December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Interim Safety Analysis of a Multicenter Randomized Prospective Double Masked Placebo Controlled Trial of Apheresis in Pre-Angiogenic Age-Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • RL Davis
    Occulogix Corporation Palm Harbor FL
  • Footnotes
    Commercial Relationships    R.L. Davis, OccuLogix Corporation F, I, E, C, P, R.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2536. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RL Davis; Interim Safety Analysis of a Multicenter Randomized Prospective Double Masked Placebo Controlled Trial of Apheresis in Pre-Angiogenic Age-Related Macular Degeneration (AMD) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2536.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: This trial evaluates the safety and efficacy of Rheopheresis blood filtration in subjects with Dry AMD. Methods: At this analysis, 43 subjects had been randomized to Rheopheresis (28) or Placebo (15) groups and had completed the 12-month follow up visit. Subjects received 343 double-masked treatments. Vascular access was obtained via bilateral antecubital venipuncture. Safety was evaluated by documenting evidence of adverse events. For each event the: dates of onset and resolution, severity, whether it was treatment-related, non-treatment-related, serious or non-serious, action or treatment required and the outcomes were recorded. Interim statistical analysis: Fischer's Exact Test compared incidence of total events in the study groups. Results: 40 adverse events (Rheopheresis - 23, Placebo - 17), both treatment-related, 5, and non-treatment-related, 35, were recorded. 17% (38 of 223) of Rheopheresis procedures encountered difficulties with venous access. Safety outcomes included episodes of parasthesisas, hypotension, nausea, edema, and others. Treatment-related adverse events were observed in 2.2% (5 of 223) of Rheopheresis procedures and in 0% (0 of120) of Placebo treatments (p=0.11). None (0 of 5) were serious. The 5 non-serious events included: hypotension (2), edema (2) and nausea (1). The incidence of non-treatment-related events was significantly greater (p=0.03) in Placebo subjects (17 in 120, 14.2%) compared to Rheopheresis subjects (18 in 223, 8.0%). The rates of serious non-treatment-related events for the 2 groups were similar (2.2% and 1.6% respectively, p=0.11). 2 distant deaths (suicide, Leukemia) occurred in the Rheopheresis group. Both occurred between the 9 and 12-month post-baseline interval. No deaths occurred in the Placebo group. No long-term treatment-related side effects, or adverse events were reported. Conclusion: This 12-month interval interim analysis demonstrates that Rheopheresis as a treatment for select patients with pre-angiogenic AMD appears to be safe and well tolerated. Adverse event rates are low were typically non-serious and self-limited. Peripheral venous access in elderly patients remains the most frequent technical challenge. These early results should stimulate further research into the use of Rheopheresis for subjects with AMD.

Keywords: 308 age-related macular degeneration • 350 clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • 353 clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.